Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-masked study of aflibercept 8 mg for macular edema secondary to retinal vein occlusion
2022-502174-16-00Phase 3Completed
- Sponsor
- Bayer
- Start
- Aug 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Countries
- 28
01
Overview
Phase 3, randomised, double-blind trial of aflibercept and fluorescein in Vein occlusion (RVO) (2 arms), sponsored by Bayer. Primary endpoint: Change from baseline in best corrected visual acuity at Week 36. Started Aug 2023; status: completed.
02
Drugs
afliberceptfluorescein
03
Conditions
Vein occlusion (RVO)
Beyond the preview
Go deeper on 2022-502174-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502174-16-00.